<DOC>
	<DOCNO>NCT02478632</DOCNO>
	<brief_summary>The purpose study evaluate change baseline bone mineral density ( BMD ) subject follow switch triple antiretroviral therapy ( ART ) regimen contain Tenofovir disoproxil fumarate ( TDF ) nucleoside reverse transcriptase inhibitor ( NRTI ) - spar two - drug regimen dolutegravir ( DTG ) + rilpivirine ( RPV ) subject participate parent study 201636 201637 ( SWORD-1 SWORD-2 ) . This open-label , parallel group , study sub-study recruit subject receive ART regimen include TDF time randomization receive treatment one two identical parent study 201636 201637 ( SWORD-1 SWORD-2 ) . These Phase III , randomise , open-label , multicentre , parallel-group , non-inferiority study evaluate efficacy , safety , tolerability switch DTG plus RPV current integrase inhibitor ( INI ) - , non NNRTI- , protease inhibitor ( PI ) -based antiretroviral regimen HIV-1-infected adult virologically suppress , HIV-1 ribonucleic acid ( RNA ) level &lt; 50 copy per millilitre ( c/mL ) . Randomisation parent study stratify baseline third agent class ( INI , NNRTI , PI ) , age group ( &lt; = &gt; 50 year old ) participation Dual energy X-ray absorptiometry ( DEXA ) sub-study , therefore also balance across treatment arm sub-study overall respect baseline third agent class age entry . The study population include approximately 75 evaluable subject recruit Early Switch DTG + RPV treatment group parent study 201636 201637 , approximately 75 evaluable subject Late Switch group continue current antiretroviral therapy ( CAR ) Week 52 across 201636 201637 ( SWORD-1 SWORD-2 ) study . Subjects participate study 202094 DEXA scan perform Day 1 study Weeks 48 , 100 148 parallel correspond scheduled visit parent study .</brief_summary>
	<brief_title>Bone Mineral Density Human Immunodeficiency Virus Type 1 ( HIV-1 ) -Infected Adult Subjects Switching From Tenofovir Regimen Dolutegravir Plus Rilpivirine Regimen</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Screened eligible yet randomise either parent study 201636 ( SWORD1 ) 201637 ( SWORD2 ) Receiving ART regimen contain TDF Female subject child bear potential negative pregnancy test Screening Day 1 agrees use one method contraception describe protocols parent study 201636 ( SWORD1 ) 201637 ( SWORD2 ) avoid pregnancy . Any contraception method must use consistently , throughout study period accordance approve product label , include adherence appropriate 'run ' period hormonal contraception Subject willing able understand requirement study participation provide sign dated write informed consent prior Screening . Subject consider appropriate candidate participation study For subject enrol France : subject eligible inclusion study either affiliate beneficiary social security category Less three vertebra range L1 L4 suitable BMD measurement DEXA scan Bilateral hip replacement Uncontrolled thyroid disease : thyroid stimulate hormone ( TSH ) normal range , consider indicate requirement thyroid replacement therapy Male hypogonadism : serum testosterone &lt; 300 nanogram per decilitre ( ng/dL ) sample collect 10:00 morning subject able willing start testosterone replacement therapy Endocrine diseases include Cushing 's syndrome diabetes mellitus History fragility fracture Ever treat osteoporosis bisphosphonates , oestrogen receptor modulators therapy , / severe osteoporosis indicate prior DEXA scan derive Tscore 3.5 low value Body mass index ( BMI ) &lt; 18 kilogram per meter ( kg/m ) ^2 = &gt; 40 kg/m^2 Vitamin D deficiency : 25 Hydroxy Vitamin D &lt; 15ng/mL Any preexist physical mental condition ( include substance abuse disorder ) , opinion investigator , may interfere subject 's ability comply schedule protocol evaluation may compromise safety subject Current use intent initiate , tamoxifen , bonerelated treatment , e.g . biphosphonates , osteoporosis medication include selective oestrogen receptor modulator medicine ( raloxifene , arzoxifene lasofoxifene ) , growth hormone anabolic steroid , except testosterone specify , study period The follow exclude unless give least 6 month prior Day 1 , plan stop study : Anticonvulsant therapy hormonal therapy , include female hormone replacement therapy testosterone replacement therapy supplement Women pregnant , breastfeed plan become pregnant breast feed study period Subject enrol , anticipate select participate follow study registration , investigational clinical protocol/s addition one parent study 201636 201637 ( SWORD1 SWORD2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>tenofovir disoproxil fumarate</keyword>
	<keyword>dolutegravir plus rilpivirine</keyword>
	<keyword>two-drug regimen</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>dual energy X-ray absorptiometry ( DEXA )</keyword>
	<keyword>Human Immunodeficiency Virus-1</keyword>
	<keyword>nucleoside reverse transcriptase inhibitor -sparing regimen</keyword>
	<keyword>integrase inhibitor</keyword>
</DOC>